主持国家自然科学基金面上项目2项,国家自然科学基金青年项目1项,四川省科技厅项目2项。近五年以第一/通讯作者发表SCI收录论著200余篇,发表在如Cancer Cell1篇(IF:48.8),Signal Transduction and Targeted Therapy4篇(IF:40.8),Cell Dis...
2.Liu SY1, Wu YL, Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. J Hematol Oncol. 2017 Jul 5;10(1):136. d 3.Zhang Q, Liao Y, Chen J, Cai B, Su Z, Ying B, et al. Epidemiology stud...
除了目前已经上市的这八个PD-1/PD-L1单抗，科学家们仍旧对PD1/PD-L1抑制剂的分子机制进行了深入的研究，2020年9月9日，Nature Communications杂志在线刊发了一篇名为“Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion”的文章。肿瘤微环境与耐药性和免疫...
DRUG resistance in cancer cellsIMMUNOTHERAPYMEMBRANE proteinsMONOCLONAL antibodiesDISEASE relapseTREATMENT effectivenessPROGRAMMED cell death 1 receptorsImmune checkpoint inhibitors (ICIs), monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4, programmed cell death 1 or its ligand PD-L1 are ...
PD-1/PD-L1抑制剂获批适应症 截止至2020年3月,FDA批准了多个免疫检查点抑制剂在多瘤肿中的适应症。 [Immune-checkpoint inhibitor approval status by the Food and Drug Administration (access date: 03/13/2020). A: accelerated, AB: antibody, CTx:chemotherapy, dMMR: mismatch repair deficiency, HCC: ...
来源:Nature Reviews Drug Discovery免疫反应可以识别、响应并消灭癌细胞。然而,在癌症发展过程中,各种细胞和分子机制发展(尤其是在肿瘤部位),以适应免疫环境的变化,并最终克服免疫攻击,使癌细胞持续生长。这些机制统称为适应性免疫抵抗(adaptive immune resistance,AIR),是癌细胞经过长期适应的结果。
近几年,肿瘤免疫治疗的好消息不断,目前已在多种肿瘤如黑色素瘤,非小细胞肺癌、肾癌和前列腺癌等实体瘤的治疗中展示出了强大的抗肿瘤活性,多个肿瘤免疫治疗药物已经获得美国FDA(Food and Drug Administration, FDA)批准临床应用。肿瘤免疫治疗由于其卓越的疗效和创新性,在2013年被《科学》杂志评为年度最重要的科学...
Hogg SJ, Beavis PA, Dawson MA, et al. Targeting the epigeneticregulation of antitumour immunity[J]. Nat Rev Drug Discov, 2020. Peng DH, Rodriguez BL, Diao L, et al. Collagen promotesanti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8(+) T cellexhaustion[J]. Nat Commun...
The PDCD1-encoded immune checkpoint receptor PD-1 is a key tumor suppressor in T cells that is recurrently inactivated in T cell non-Hodgkin lymphomas (T-NHLs). The highest frequencies of PDCD1 deletions are detected in advanced disease, predicting inferior prognosis. However, the tumor-suppress...
▲ 图片来源:https://www.creative-biolabs.com/drug-discovery/therapeutics/humanized-lag3-immune-checkpoint-knock-in-mice.htm LAG-3的免疫抑制功能恰巧与PD-1的耐受机制相符:LAG-3不但抑制具有抗肿瘤活性的CD8+ T细胞的增殖,而且直接影响其免疫功能,与此同时,LAG-3还能增强调节性T细胞的抑制活性,进一步抑制免疫...